Overview

Location [1]
11q22.2
Protein [2]
Baculoviral IAP repeat-containing protein 3
Synonyms [1]
AIP1, HIAP1, MIHC, CIAP2, c-IAP2, HAIP1, RNF49, MALT2, API2

Baculovial IAP repeat containing 3 (BIRC3) is a gene that encodes encodes the protein cellular inhibitor of apoptosis protein 2 (cIAP2), which inhibits apoptosis. BIRC3 is localized to chromosome 11q22, whose deletion is associated with high risk disease in patients with chronic lymphocytic leukemia. BIRC3 mutations are observed in <5% of patients with CLL (PMID: 24943832; PMID: 24597984; PMID: 24217197; PMID: 22308293; PMID: 25605254), ~11% of patients with Splenic marginal zone lymphoma (PMID: 21881048) and 6-10% of mantle cell lymphoma cases (PMID: 24362935).

BIRC3 is altered in 1.01% of all cancers with melanoma, non-small cell lung carcinoma, breast carcinoma, colorectal adenocarcinoma, and sarcoma having the greatest prevalence of alterations [3].

BIRC3 GENIE Cases - Top Diseases

The most common alterations in BIRC3 are BIRC3 Mutation (0.35%), BIRC3 Amplification (0.21%), BIRC3 Loss (0.07%), BIRC3 Frameshift (0.02%), and BIRC3 Nonsense (0.02%) [3].

BIRC3 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of BIRC3 in Diseases

Marginal Zone Lymphoma +

Mature B-Cell Lymphoma/Leukemia +

Lymphoma +

Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

Chronic Lymphocytic Leukemia +

Chronic Myeloid Leukemia +

Multiple Myeloma +

Myelodysplastic Syndromes +

Prolymphocytic Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.